Lugon J R, Strogoff de Matos J P
Nephrology Division, Department of Medicine, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
Clin Nephrol. 2010 Nov;74 Suppl 1:S66-71.
South America is one of the most heterogeneous regions in the world regarding ethnical composition and socioeconomic development level. Our aim was to analyze the status of end-stage renal disease (ESRD) management in the Portuguese-speaking and Spanish-speaking countries of South America. Data were collected using a survey sent to the Society of Nephrology of each country, and complemented with data available in the Latin American Dialysis and Transplant Registry or personal communication with collaborators within the nephrology societies. Most of South America countries have a hybrid of public and private healthcare system. Universal access to renal replacement therapy (RRT) is provided in Argentina, Brazil, Chile, Uruguay and Venezuela which comprise nearly 73% of South America population. The expenditure on health per capita varies from nearly US$ 200 per year in Bolivia to more than US$ 1,600 per year in Argentina. The prevalence of patients on RRT varies from 95 pmp. in Paraguay and 924 pmp in Chile. There is an important association between the prevalence of diabetes and the number of patients on RRT. Older people also are at a higher risk of developing ESRD. The rapid aging of the population and a higher prevalence of diabetes will probably translate into a burden of ESRD in the future. It is to be hoped that political and economical stability in the region can ease the adoption of universal access to ESRD treatment in all South American countries.
就种族构成和社会经济发展水平而言,南美洲是世界上最多样化的地区之一。我们的目的是分析南美洲讲葡萄牙语和西班牙语国家的终末期肾病(ESRD)管理状况。数据通过向每个国家的肾脏病学会发送调查问卷收集,并辅以拉丁美洲透析和移植登记处提供的数据或与肾脏病学会内的合作者的个人交流。南美洲大多数国家都有公共和私人医疗保健系统的混合体。阿根廷、巴西、智利、乌拉圭和委内瑞拉提供普遍的肾脏替代治疗(RRT),这些国家占南美洲人口的近73%。人均卫生支出从玻利维亚每年近200美元到阿根廷每年超过1600美元不等。接受RRT治疗的患者患病率从巴拉圭的每百万人口95例到智利的每百万人口924例不等。糖尿病患病率与接受RRT治疗的患者数量之间存在重要关联。老年人患ESRD的风险也更高。人口的快速老龄化和糖尿病的较高患病率可能会在未来转化为ESRD的负担。希望该地区的政治和经济稳定能够促进所有南美洲国家普遍获得ESRD治疗。